U.S. Capital Wealth Advisors’s GSK GSK Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$357K	Sell	6,461 -168,623	-96%	-$9.14M	0.01%	764
2025 Q4	$8.59M	Sell	175,084 -83,906	-32%	-$3.91M	0.22%	109
2025 Q3	$11.2M	Buy	258,990 +2,683	+1%	+$105K	0.3%	78
2025 Q2	$9.84M	Buy	256,307 +15,336	+6%	+$586K	0.29%	84
2025 Q1	$9.34M	Buy	240,971 +23,648	+11%	+$866K	0.29%	88
2024 Q4	$7.35M	Sell	217,323 -25,722	-11%	-$926K	0.23%	109
2024 Q3	$9.94M	Buy	243,045 +1,072	+0.4%	+$43.9K	0.35%	68
2024 Q2	$9.32M	Buy	241,973 +11,359	+5%	+$478K	0.35%	64
2024 Q1	$9.89M	Sell	230,614 -2,957	-1%	-$122K	0.38%	57
2023 Q4	$8.66M	Buy	233,571 +12,443	+6%	+$447K	0.34%	66
2023 Q3	$8.02M	Buy	221,128 +27,753	+14%	+$985K	0.36%	60
2023 Q2	$6.89M	Buy	193,375 +27,908	+17%	+$1M	0.33%	78
2023 Q1	$5.89M	Sell	165,467 -1,308	-0.8%	-$45.8K	0.27%	84
2022 Q4	$5.86M	Sell	166,775 -42,203	-20%	-$1.41M	0.27%	82
2022 Q3	$6.15M	Buy	208,978 +22,256	+12%	+$844K	0.31%	74
2022 Q2	$10.2M	Buy	186,722 +6,324	+4%	+$349K	0.45%	39
2022 Q1	$9.82M	Buy	180,398 +15,743	+10%	+$855K	0.36%	51
2021 Q4	$9.08M	Buy	164,655 +4,604	+3%	+$239K	0.36%	65
2021 Q3	$7.64M	Buy	+160,051	New	+$8.04M	0.33%	72

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

U.S. Capital Wealth Advisors's GSK Position: Q1 2026 in Review

U.S. Capital Wealth Advisors reduced its GSK (GSK) stake by 96% in Q1 2026, selling an estimated $9.14M and leaving 6,461 shares worth $357K. The position accounts for 0.01% of the portfolio, ranked #764.

U.S. Capital Wealth Advisors first reported a position in GSK in Q3 2021 and has held it in 19 quarters since. The position peaked at $11.2M in Q3 2025. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

U.S. Capital Wealth Advisors held 6,461 shares of GSK worth $357K as of Q1 2026.
U.S. Capital Wealth Advisors sold 168,623 GSK shares in Q1 2026, an estimated $9.14M.
GSK made up 0.01% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #764 holding.
U.S. Capital Wealth Advisors first reported a position in GSK in Q3 2021 and has held it in 19 quarters since.
U.S. Capital Wealth Advisors's GSK position peaked at $11.2M in Q3 2025.
1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.